Sugi Predict

Sugi Predict / Compounds / SCHEMBL692379

SCHEMBL692379

SCHEMBL692379

CCN(Cc1ccccc1)c1ccc(-c2cccc(NS(=O)(=O)N(C)C)c2)nn1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PRMT6 Q96LA8 2/20 0.43
▸ NR3C1 P04150 1/20 0.43
▸ MEN1 O00255 2/20 0.42
▸ KMT2A Q03164 2/20 0.42
▸ MAPT P10636 3/20 0.42
▸ LMNA P02545 2/20 0.42
▸ POLB P06746 1/20 0.42
▸ ENPP2 Q13822 1/20 0.41
▸ BRD4 O60885 1/20 0.41
▸ TP53 P04637 3/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ AR P10275 1/20 0.39
▸ ALDH1A1 P00352 2/20 0.39
▸ CYP1A2 P05177 2/20 0.39
▸ CYP3A4 P08684 2/20 0.39
▸ HSD17B10 Q99714 2/20 0.39
▸ CYP2D6 P10635 1/20 0.39
▸ CYP2C19 P33261 1/20 0.39
▸ CLK4 Q9HAZ1 1/20 0.39
▸ THRB P10828 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL692966 0.90 NR3C1 (0.56) NR3C1MEN1KMT2ALMNAPOLB
SCHEMBL692774 0.86 NR3C1 (0.44) PRMT6NR3C1MAPTLMNAPOLB
SCHEMBL692541 0.84 NPC1 (0.53) MEN1KMT2AMAPTLMNAPOLB
SCHEMBL692595 0.83 TP53 (0.45) MEN1KMT2AMAPTLMNAPOLB
SCHEMBL1369219 0.77 ENPP2 (0.42) MEN1KMT2AMAPTLMNAENPP2
SCHEMBL7710033 0.76 ENPP2 (0.38) NR3C1MAPTENPP2TP53SMN1; SMN2
SCHEMBL3242528 0.72 ENPP2 (0.45) KMT2AENPP2TP53SMN1; SMN2TSHR
SCHEMBL1369562 0.69 TP53 (0.40) MAPTPOLBENPP2TP53SMN1; SMN2
SCHEMBL11409417 0.68 HTT (0.54) NR3C1MEN1KMT2AMAPTLMNA
SCHEMBL14194063 0.68 HPGD (0.65) MEN1KMT2AMAPTPOLBTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103068390-A Compounds, compositions, and methods comprising pyridazine sulfonamide derivatives INST ONEWORLD HEALTH 2013-04-24 — — CN claimed
EP-2560654-A1 COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES Institute for OneWorld Health (US) 2013-02-27 — — EP claimed
US-20120129858-A1 COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES INSTITUTE FOR ONEWORLD HEALTH 2012-05-24 — — US claimed
CN-102458122-A Compounds, compositions and methods comprising pyridazine sulfonamide derivatives INST ONEWORLD HEALTH 2012-05-16 — — CN claimed
EP-2421368-A1 COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES Institute for OneWorld Health (US) 2012-02-29 — — EP claimed
US-20110288093-A1 Compounds, Compositions, and Methods Comprising Pyridazine Sulfonamide Derivatives INSTITUTE FOR ONEWORLD HEALTH 2011-11-24 — — US claimed
WO-2011133600-A1 COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES INSTITUTE FOR ONEWORLD HEALTH (US) 2011-10-27 — — WO claimed
WO-2010123822-A1 COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES INSTITUTE FOR ONEWORLD HEALTH (US) 2010-10-28 — — WO claimed
CN-103068390-A Compounds, compositions, and methods comprising pyridazine sulfonamide derivatives INST ONEWORLD HEALTH 2013-04-24 — — CN disclosed
US-20120129858-A1 COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES INSTITUTE FOR ONEWORLD HEALTH 2012-05-24 — — US disclosed
US-20120129858-A1 COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES INSTITUTE FOR ONEWORLD HEALTH 2012-05-24 — — US disclosed
US-20120129858-A1 COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES INSTITUTE FOR ONEWORLD HEALTH 2012-05-24 — — US disclosed
CN-102458122-A Compounds, compositions and methods comprising pyridazine sulfonamide derivatives INST ONEWORLD HEALTH 2012-05-16 — — CN disclosed
EP-2421368-A1 COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES Institute for OneWorld Health (US) 2012-02-29 — — EP disclosed
US-20110288093-A1 Compounds, Compositions, and Methods Comprising Pyridazine Sulfonamide Derivatives INSTITUTE FOR ONEWORLD HEALTH 2011-11-24 — — US disclosed
US-20110288093-A1 Compounds, Compositions, and Methods Comprising Pyridazine Sulfonamide Derivatives INSTITUTE FOR ONEWORLD HEALTH 2011-11-24 — — US disclosed
US-20110288093-A1 Compounds, Compositions, and Methods Comprising Pyridazine Sulfonamide Derivatives INSTITUTE FOR ONEWORLD HEALTH 2011-11-24 — — US disclosed
WO-2010123822-A1 COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES INSTITUTE FOR ONEWORLD HEALTH (US) 2010-10-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120129858-A1 COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES CFTR, PKD1, PKD2 PRMT6 4112/4885NR3C1 3998/4885MEN1 2920/4885
US-20110288093-A1 Compounds, Compositions, and Methods Comprising Pyridazine Sulfonamide Derivatives SCN1A, CLIC1, CLCN2 PRMT6 4209/4885NR3C1 3488/4885MEN1 1196/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.